Kallyope Inc. has synthesized glucose-dependent insulinotropic receptor (GDIR; GPR119) agonists reported to be useful for the treatment of metabolic and nutrition disorders.

Kallyope Inc., a company leveraging connections between the gut and brain to develop new medicines for diabetes, obesity and other diseases, has raised $236 million in series D financing to support its work. Readouts of early clinical data for its most advanced programs, phase I small molecules for metabolic disease and gut barrier conditions, will start to arrive later this year, company CEO and President Jay Galeota told BioWorld.